Ovarian Cancer

Recent results with adavosertib in ovarian cancer could signal future positive results, given the number of trials using the targeted therapy with the PARP inhibitor olaparib.

Lauren M. Corduck, who turned a diagnosis of ovarian cancer into a crusade to educate others with similar genetic mutations, died on December 24, 2020. She was 49.

Certain elderly women with ovarian cancer might benefit from aggressive treatment methods, a study recently published in Annals of Surgical Oncology found.

Panel testing for genetic variants linked to more cancers is cost-effective than just testing or BRCA1/2 mutations, says a clinical director for a women's health company.

Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.

A study links the size of cysts associated with endometriosis with coexistent ovarian cancer.

A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Kazia Therapeutics will report the full results at a future scientific meeting.

One patient had a complete response and the majority of patients achieved disease control at 12 weeks.

New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.

Tumor mutational burden is an emerging biomarker to predict response to immune checkpoint inhibitors, but its utility as a prognostic indicator in ovarian cancer is unclear.

The new report suggests that patients treated with prolonged poly-ADP-ribose polymerase inhibitors after chemotherapy may need close hematological monitoring.

The dearth of effective treatment options for patients with ovarian cancer not only leads to poor health outcomes, but also leads to psychological distress, according to new research.

Drawing on data from 6 randomized controlled trials accounting for over 2200 patients, the researchers the researchers compared the efficacy and safety of olaparib, rucaparib, and niraparib.

Once identified, ovarian tumors are usually surgically removed due to the presumed risk of complications associated with the diagnosis. Researchers recently looked to evaluate the incidence of cyst complications and malignancy during the first 2 years of follow-up after the tumors were classified as benign.

A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.